
Product Data Sheet

Alexa Fluor® 647 anti-human IL-10

Catalog # / Size:	3107070 / 25 tests 3107060 / 100 tests
Clone:	JES3-9D7
Isotype:	Rat IgG1, к
Immunogen:	COS - expressed, recombinant human IL-10
Reactivity:	Human
Preparation:	The antibody was purified by affinity chromatography, and conjugated with Alexa Fluor® 647 under optimal conditions.
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).
Concentration:	Lot-specific



LPS-stimulated (overnight) human peripheral blood monocytes surface stained with with CD14 (M5E2) PE and intracellularly stained with JES3-9D7 Alexa Fluor® 647

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per 10 ⁶ cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.
	* Alexa Fluor $^{ m I\!R}$ 647 has a maximum emission of 668 nm when it is excited at 633nm / 635nm.
Application Notes:	ELISA Capture ¹⁻⁵ or ELISPOT Capture ⁶ : The purified JES3-9D7 antibody is useful as the capture antibody in a sandwich ELISA, when used in conjunction with the biotinylated JES3-12G8 antibody (Cat. No. 501502) as the detecting antibody and recombinant human IL-10 (Cat. No. 571009) as the standard. The LEAF [™] purified antibody is suggested for ELISPOT capture. Neutralization ^{1-3,9} : The LEAF [™] purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human IL-10 bioactivity (Cat. No. 501407). The JES3-9D7 antibody can neutralize the bioactivity of natural or recombinant IL-10. Additional reported applications (for the relevant formats) include: immunohistochemical staining ¹² . Note: For testing human IL-10 in serum or plasma, BioLegend's ELISA Max [™] Sets (Cat. No. 430601 to 430606) are specially developed and recommended. The JES3-9D7 antibody reacts with human and viral interleukin-10 (IL-10).
Application References:	 Abrams J, <i>et al.</i> 1992. <i>Immunol. Rev.</i> 127:5. (ELISA Capture, Neut) Gotlieb W, <i>et al.</i> 1992. <i>Cytokine</i> 4:385. (ELISA Capture, Neut) Yssel H, <i>et al.</i> 1992. <i>J. Immunol.</i> 149:2378. (ELISA Capture, Neut) Abrams J. 1995. <i>Curr. Prot. Immunol.</i> John Wiley and Sons New York. Unit 6.20. (ELISA Capture) Burdin N, <i>et al.</i> 1993. <i>J. Exp. Med.</i> 177:295. (ELISA Capture) Klinman D, <i>et al.</i> 1994. <i>Curr. Prot. Immunol.</i> John Wiley and Sons New York. Unit

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com 6.19. (ELISPOT Capture)
7. Schaerli P, *et al.* 2000. *J. Exp. Med.* 192:1553.
8. Jason J, *et al.* 1999. *Clin. Diagn. Lab Immunol.* 6:73.
9. Akdis CA, *et al.* 1998. *J. Clin. Invest.* 102:98. (Neut)
10. Stary G, *et al.* 2011. *J. Immunol.* 186:103. <u>PubMed</u>
11. Mason GM, *et al.* 2012. *PNAS.* <u>PubMed</u>
12. Smith DR, *et al.* 1994. *Am. J. Pathol.* 145:18. (IHC)

Description: IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production.
 Antigen References: 1. Fitzgerald K, *et al.* Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. de Waal-Malefyt R, *et al.* 1992. *Curr. Opin. Immunol.* 4:314.

- 2. Ue Wadi-Maleryl R, *et al.* 1992. *Curr. Opin. Infinutiol.*
- 3. Howard M, et al. 1992. Immunol. Today. 13:198.